timothy sykes logo
Breakthrough Discovery: Babesia and Chronic Disease Link Uncovered Thumbnail
ADD US ONG Google News

Breakthrough Discovery: Babesia and Chronic Disease Link Uncovered

MATT MONACO•UPDATED JAN. 22, 2026, 9:19 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

60 Degrees Pharmaceuticals Inc. stocks have been trading up by 174.5 percent following positive news and investor confidence.

Candlestick Chart

Live Update At 09:19:00 EST: On Thursday, January 22, 2026 60 Degrees Pharmaceuticals Inc. stock [NASDAQ: SXTP] is trending up by 174.5%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent months, SXTP has taken a beating in the stock market, as seen by its wild swings and volatility. A look at SXTP’s multi-day chart paints a volatile picture with fluctuations reminiscent of a roller coaster.

The stock was valued at $2.05 at the start of the year and witnessed a tumultuous ride, closing at $2 on Jan 26, 2026. Watching the stock’s numbers feels like cheering for an underdog in the finals—a suspenseful spectacle where every point counts.

Financially speaking, SXTP’s earnings have glittered with some shiny spots amid clouds of financial strain. The company has reported a total revenue of just over $607,000 with a gross margin of 16.5%, indicating efforts to paddle through torrential economic challenges. Its profit margin, though, has been dragging down like a heavy anchor at -921.94%.

Investment metrics like the P/E ratio hovering at 1.05 suggest that investors might not be paying too much premium for future growth. The company’s current ratio at 2.9 indicates a capability to settle short-term obligations, painting one of the few silver streaks in an otherwise cloudy financial state.

Analysts are keeping a wary eye on SXTP’s revenues and profitability ratios due to its lower pricing-to-book value. It’s like trying to catch fireflies in the dark—a challenging pursuit given the economic hurdles.

A Glimpse at Market Impacts

The newly discovered link between babesia infection and chronic disease has shaken the medical world like a whirlwind. Such discoveries bear significant market potential, especially in pharmaceuticals where innovation is the key currency.

60 Degrees Pharmaceuticals plays a pioneering role here, spearheading the B-Free Chronic Babesiosis Study to evaluate the ARAKODA regimen. This breakthrough can mark a victorious stride akin to discovering a treasure chest after an arduous quest.

In this context, market sentiments are cautiously optimistic. If the study proves conclusive, SXTP might find itself on traders’ radar, with its shares poised for an upward flight. Still, investors proceed with caution. As the saying goes, look before you leap—a mantra traders hold dear.

The firm’s focus on chronic disease treatments could transform what feels like uncharted territory into a profitable domain, changing lives as it grows. But only time will tell how this discovery unfolds in the real world of stocks and medicine.

More Breaking News

A Conclusion on the Horizon

In the end, 60 Degrees Pharmaceuticals stands at a crossroad, where pioneering science meets market opportunity. Innovation and proof of concept are what can propel SXTP forward or leave it suspended in the quagmire of research uncertainties. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This mindset is crucial as traders consider SXTP’s potential amidst the volatile ebb and flow of market trends.

There’s a peculiar exhilaration in watching how discoveries like these morph the economic landscape. As the company presses forward with its study, all market eyes will be glued to their progress—as SXTP might yet write its own story of triumph amidst trials.

In this intricate dance of science and stocks, SXTP holds a flickering flame of potential. The world watches closely to see if it ignites the market and cures what ails countless lives.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SXTP

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”